Tackling Antimicrobial Resistance Together: A Conversation with Dr. Beverley Isherwood

In­cyte’s mon­o­clon­al an­ti­body Mon­ju­vi re­duced cer­tain fol­lic­u­lar lym­phoma pa­tients’ risk of pro­gres­sion, re­lapse or death by 57% com­pared to place­bo, the com­pa­ny an­nounced Mon­day. …

A New Jer­sey fed­er­al judge is al­low­ing John­son & John­son to bring new chal­lenges to ev­i­dence brought by plain­tiffs in the com­pa­ny’s mul­ti­dis­trict talc lit­i­ga­tion.